Update: Establishing a Clinically Meaningful Predictive Model of Hematologic Toxicity in Nonmyeloablative Targeted Radiotherapy: Practical Aspects and Limitations of Red Marrow Dosimetry
- 1 April 2005
- journal article
- review article
- Published by SAGE Publications in Cancer Biotherapy and Radiopharmaceuticals
- Vol. 20 (2) , 126-140
Abstract
In either heavily pretreated or previously untreated patient populations, dosimetry holds the promise of playing an integral role in the physician's ability to adjust therapeutic activity prescriptions to limit excessive hematologic toxicity in individual patients. However, red marrow absorbed doses have not been highly predictive of hematopoietic toxicity. Although the accuracy of red marrow dose estimates is expected to improve as more patient-specific models are implemented, these model-calculated absorbed doses more than likely will have to be adjusted by parameters that adequately characterize bone marrow tolerance in the heavily pretreated patients most likely to receive nonmyeloablative radiolabeled antibody therapy. Models need to be established that consider not only absorbed dose but also parameters that are indicative of pretherapy bone marrow reserve and radiosensitivity so that a clinically meaningful predictive model of hematologic toxicity can be established.Keywords
This publication has 22 references indexed in Scilit:
- Comparison of Methods for Predicting Myelotoxicity for Non-Marrow Targeting I-131-Antibody TherapyCancer Biotherapy and Radiopharmaceuticals, 2003
- Sensitivity of Model-Based Calculations of Red Marrow Dosimetry to Changes in Patient-Specific ParametersCancer Biotherapy and Radiopharmaceuticals, 2002
- Chemotherapy and Bone Marrow Reserve: Lessons Learned from Autologous Stem Cell TransplantationCancer Biotherapy and Radiopharmaceuticals, 2002
- Time dependence of the activity concentration ratio of red marrow to blood and implications for red marrow dosimetryCancer, 2002
- Radiation Dosimetry for Radionuclide Therapy in a Nonmyeloablative StrategyCancer Biotherapy and Radiopharmaceuticals, 2002
- Plasma FLT3‐L levels predict bone marrow recovery from myelosuppressive therapyCancer, 2000
- Radiation Absorbed Dose Estimation for 90 Y-DOTA-biotin with Pretargeted NR-LU-10/StreptavidinCancer Biotherapy and Radiopharmaceuticals, 1999
- Estimation of Radiation Absorbed Doses to the Red Marrow in RadioimmunotherapyClinical Nuclear Medicine, 1995
- Predictive estimate of blood dose from external counting data preceding radioiodine therapy for thyroid cancerNuclear Medicine and Biology, 1993
- The relation of weight of haematopoietic marrow to body weightBritish Journal of Radiology, 1984